Antinol® EAB-277® – The Executive Summary

Antinol® EAB-277® – The Executive Summary

The Summary of the researches and publications on




Antinol® Rapid is a potent synergistic blend of 2 marine lipid extracts chosen for their unique enhancement formula called EAB-277®.

EAB-277® is the key active ingredient of this advanced formula formulated to promote optimal benefits through its synergistic efficacy contains > 90 free fatty acids full spectrum of Omega 3 including ETA, EPA, DHA as well as other key Polyunsaturated fatty acids (PUFAs) and antioxidants.

The two marine lipids used in Antinol® Rapid are proprietary and exclusively produced. The exact combination of 30mg lipid fractions from Perna canaliculus (New Zealand green lipped mussel) and 20mg high phospholipid krill oil is the result of years of research combining and isolating lipid groups and essential fatty acids to find the optimal nutrient synergy.

EAB-277®’s proprietary high phospholipid krill oil is high in polar lipid enrichment which enhances bioactivity “Potency” of this marine oil blend formula as a result of proven efficacy.

The Antinol® Rapid EAB-277® blend has been proven via laboratory tests to be more effective than either of the individual lipids alone in inhibiting inflammation markers such as nitric oxide, TNFα, and IL-6.


Antinol® Rapid Animal Clinical Studies:


  1. Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524® and EAB-277®), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial.
  2. Randomized placebo-controlled trial to evaluate the efficacy of Oil extract of the seed of Biota Orientalis (4CYTE™ Epiitalis® Forte) compared with: (i) placebo, (ii) NSAID: Meloxicam (Boehringer Ingelheim) and (iii) the marine based fatty acid compound, EAB-277® (“Antinol® Rapid”) for the treatment of osteoarthritis in dogs.

  3. Randomized placebo-controlled trial to evaluate the effects of PCSO-524® (Antinol®) and EAB-277® (Antinol® Rapid) on weight bearing in the treatment of canine osteoarthritis by comparison with the administration of the compounds: (i) NSAID: Meloxicam (Metacam, Boehringer Ingelheim Animal Health), (ii) PCSO-524®, (iii) EAB-277®, (iv) a combination of PCSO-524® with Meloxicam and (v) placebo.

  4. A Randomized Placebo Controlled Trial – Preliminary Study of the effects of PCSO-524® and EAB-277® on Renal Protective Function in the case of long term NSAID use for osteoarthritis in dogs.

  5. The Effect of EAB-277® on Heart Rate Variability (HRV) in Dogs with Tracheal Collapse.

  6. Supplementary effect of EAB-277® in Combination with Prednisolone against Immune-Mediated Hemolytic Anemia in Dogs.

  7. Tracheal Collapse Study in Small Dogs.

  8. Effects of marine based fatty acid compound EAB-277® on coagulopathy in dogs.

  9. Safety Study of EAB-277® (Antinol® Rapid) in Dogs.

  10. Safety Study of EAB-277® (Antinol® Rapid) in Cats.

Copy Citation

Antinol EAB-277® - Executive Summary